Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24416920 | 0.77 | CYP11B1 (0.42) | KDM4ELMNAMAPTGFERHTR2A | |
| SCHEMBL28514719 | 0.73 | TRPV4 (0.36) | PGR | |
| SCHEMBL28507857 | 0.71 | IMPDH2 (0.44) | KDM4EMAPT | |
| SCHEMBL18348160 | 0.71 | PGR (0.44) | PGR | |
| SCHEMBL24877474 | 0.68 | SLC6A2 (0.38) | — | |
| SCHEMBL2650777 | 0.68 | LPL (0.44) | GPR35 | |
| SCHEMBL28712582 | 0.67 | CES2 (0.37) | — | |
| SCHEMBL573864 | 0.66 | MAOB (0.53) | KDM4E | |
| SCHEMBL5115814 | 0.66 | ADRA1D (0.43) | — | |
| SCHEMBL27187843 | 0.66 | CYP11B1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108566-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3191468-B1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-12 | — | — | EP | disclosed |
| EP-3191468-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| US-9611262-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| WO-2016040789-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
| US-20160075696-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075696-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY2R | PGR 614/4885GPR35 77/4885KDM4E 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.